Abstract COVID‐19, caused by SARS‐CoV‐2 infection, continues to be a major public
health crisis around the globe. Development of vaccines and the first cluster of antiviral …

The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a
challenge to global health. At present, many candidate small-molecule therapeutics have …

The severe acute respiratory syndrome–coronavirus 2 (SARS‐CoV‐2), the infectious agent
responsible for COVID‐19–has caused more than 2.5 million deaths worldwide and …

Despite several major achievements in the development of vaccines and antivirals, the fight
against SARS-CoV-2 and the health problems accompanying COVID-19 are still ongoing …

As the pathogen of COVID‐19, SARS‐CoV‐2 encodes two essential cysteine proteases that
process the pathogen's two large polypeptide products pp1a and pp1ab in the human cell …

In this paper, an environmentally benign, convenient, and efficient one-pot three-component
reaction has been developed for the regioselective synthesis of novel 5-aroyl (or …

Ubiquitin-like proteins (Ubls) share some features with ubiquitin (Ub) such as their globular
3D structure and the ability to attach covalently to other proteins. Interferon Stimulated Gene …

Although vaccines are obviously mitigating the COVID-19 pandemic diffusion, efficient
complementary antiviral agents are urgently needed to combat SARS-CoV-2. The viral …

The two SARS‐CoV‐2 proteases, ie the main protease (Mpro) and the papain‐like protease
(PLpro), which hydrolyze the viral polypeptide chain giving functional non‐structural …

Despite significant studies on the COVID-19 pandemic, scientists around the world are still
battling to find a definitive therapy against the ongoing severe global health crisis. In this …